Abstract:
An organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which a compound represented by the following formula (I) is contained in any layer of the at least one organic layer. The organic electroluminescent element has high luminous efficiency and a strong effect of improving the durability by driving aging: wherein X, A1, A2, A3, A4, and R1 to R8 are as defined herein.
Abstract:
A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
Abstract:
An optical assembly (OSA) that installs a semiconductor optical device mounted on a thermo-electric controller (TEC) is disclosed. The TEC in the upper plate thereof is mechanically connected to the housing, or to the block stiffly fixed to the housing by a bridge made of stiff material. The bridge preferably extends along the optical axis to show enhanced durability against the impact caused by an external ferrule abutting against the receptacle of the OSA.
Abstract:
In order to provide an organic electroluminescence device with high luminous efficiency and good durability, the present invention provides a charge transporting material including a compound represented by Formula (Cz-1) wherein the content of a particular halogen-containing impurity in the charge transporting material is from 0.000% to 0.10% when the content is calculated as a proportion of the absorption intensity area of the impurity with respect to the total absorption intensity area of the charge transporting material, as measured by high-performance liquid chromatography at a measurement wavelength of 254 nm, and an organic electroluminescence device wherein the charge transporting material is included in an organic layer: wherein in Formula (Cz-1), each of R1 to R5 independently represents a particular atom or group; and each of n1 to n5 independently represents a particular integer.
Abstract:
The organic electroluminescence device has, on a substrate thereof, a pair of electrodes and at least one organic layer including a light emitting layer between the electrodes, wherein the light emitting layer contains a phosphorescent complex material containing a specific monoanionic bidentate ligand and the device contains, in a layer sandwiched between the light emitting layer and a cathode, a compound represented by the following formula (1): (Cz)p-L-(A)q (1) wherein, Cz represents a substituted or unsubstituted arylcarbazolyl or carbazolylaryl, L represents a single bond or a substituted or unsubstituted arylene, cycloalkylene, or aromatic heterocycle, A represents a substituted or unsubstituted nitrogen-containing 6-membered aromatic heterocycle, and each of p and q independently represents an integer from 1 to 6.
Abstract:
An electronic device, including a substrate, a functional structure constituting a functional element formed on the substrate, and a cover structure forming a cavity portion in which the functional structure is disposed, is disclosed. In the electronic device, the cover structure includes a laminated structure of an interlayer insulating film and a wiring layer, the laminated structure being formed on the substrate in such a way that it surrounds the cavity portion, and the cover structure has an upside cover portion covering the cavity portion from above, the upside cover portion being formed with part of the wiring layer that is disposed above the functional structure.
Abstract:
A light emitting organic thin film including at least one compound represented by Formula (PQ-1) and at least one compound represented by Formula (BN-1). In Formula (PQ-1), each of Ra, Rb and Rc independently represents a hydrogen atom or an alkyl group, wherein any one of Ra, Rb and Rc represents a hydrogen atom and the remaining two represent an alkyl group. Each of R1 to R5 independently represents a hydrogen atom, an alkyl group, an aryl group, a fluorine atom or a cyano group. Each of Rx and Ry independently represents an alkyl group or a phenyl group. In Formula (BN-1), Ar1 represents an arylene group that may have a substituent Z. Ar2 represents a condensed hydrocarbyl group that may have a substituent Z. Each of R101 to R113 independently represents a phenyl group, or the like.
Abstract translation:包含至少一种由式(PQ-1)表示的化合物和至少一种由式(BN-1)表示的化合物的发光有机薄膜。 在式(PQ-1)中,Ra,Rb和Rc各自独立地表示氢原子或烷基,其中Ra,Rb和Rc中的任一个表示氢原子,其余两个表示烷基。 R 1〜R 5各自独立地表示氢原子,烷基,芳基,氟原子或氰基。 Rx和Ry各自独立地表示烷基或苯基。 在式(BN-1)中,Ar 1表示可以具有取代基Z的亚芳基.Ar2表示可以具有取代基Z的稠合烃基.R101至R113中的每一个独立地表示苯基等。
Abstract:
As an organic electroluminescence device that exhibits superior external quantum efficiency and durability during driving at high temperature, and small variation in chromaticity and small increase in voltage after driving at high temperatures and has long lifespan, it is provided that the organic electroluminescence device including on a substrate a pair of electrodes and at least one layer of an organic layer including a light emitting layer disposed between the electrodes, wherein the light emitting layer contains at least one specific iridium complex and any layer of the at least one layer of an organic layer contains at least one compound represented by Formula (1): wherein in Formula (1), each of R1 to R5 independently represents a specific group or atom, n1 represents an integer of 0 to 5, and each of n2 to n5 independently represents an integer of 0 to 4.
Abstract:
[Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.
Abstract:
A vibration circuit includes: a micro electro mechanical systems (MEMS) vibrator which includes a first electrode and a second electrode which are arranged with a gap therebetween; an amplification section which includes a gain section which has a first input terminal and a first output terminal and of which gain is greater than 1, and a gain restriction section which includes a second input terminal and a second output terminal and of which the gain is less than 1; and an output terminal which is connected to the first output terminal, wherein the first electrode is connected to the first input terminal, wherein the first output terminal is connected to the second input terminal, and wherein the second output terminal is connected to the second electrode.